Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,884
  • Shares Outstanding, K 20,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,170 K
  • 36-Month Beta 1.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.15 +27.64%
on 10/18/17
8.80 -10.80%
on 10/25/17
+1.15 (+17.16%)
since 10/17/17
3-Month
6.11 +28.48%
on 08/18/17
8.80 -10.80%
on 10/25/17
+1.38 (+21.24%)
since 08/17/17
52-Week
5.60 +40.18%
on 08/16/17
11.75 -33.19%
on 02/17/17
-3.30 (-29.60%)
since 11/17/16

Most Recent Stories

More News
Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2017...

CDTX : 7.85 (+3.29%)
Cidara Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Cidara Therapeutics, Inc. (NASDAQ: CDTX) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:05 PM Eastern...

CDTX : 7.85 (+3.29%)
5 Biotech Stocks Well Poised to Surpass Expectations in Q3

The pharma and biotech industry has demonstrated strength

PBYI : 105.50 (+2.28%)
RGEN : 33.40 (-0.98%)
CDTX : 7.85 (+3.29%)
INO : 4.72 (+1.72%)
SBBP : 5.65 (+4.63%)
What's in the Cards for Merrimack (MACK) in Q3 Earnings?

Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

AGEN : 3.70 (-0.27%)
RGNX : 27.55 (-1.96%)
CDTX : 7.85 (+3.29%)
MACK : 11.75 (+0.86%)
What's in the Cards for Repros (RPRX) This Earnings Season?

Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

AGEN : 3.70 (-0.27%)
RPRX : 0.38 (+2.70%)
RGNX : 27.55 (-1.96%)
CDTX : 7.85 (+3.29%)
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after...

CDTX : 7.85 (+3.29%)
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its...

CDTX : 7.85 (+3.29%)
Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its novel echinocandin...

CDTX : 7.85 (+3.29%)
Cidara Therapeutics to Present at Two Upcoming Conferences

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer...

CDTX : 7.85 (+3.29%)
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., the company's president and chief...

CDTX : 7.85 (+3.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

2nd Resistance Point 7.99
1st Resistance Point 7.92
Last Price 7.85
1st Support Level 7.74
2nd Support Level 7.63

See More

52-Week High 11.75
Fibonacci 61.8% 9.40
Fibonacci 50% 8.68
Fibonacci 38.2% 7.95
Last Price 7.85
52-Week Low 5.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart